Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

180.25 +2.70 (+1.52%)
Streaming Delayed Price Updated: 10:38 AM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
56 57 Next >
News headline image
Microsoft, Snap And 2 Other Stocks Insiders Are Selling ↗
The S&P 500 closed lower more than 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Biotech Is Back With Guggenheim Upgrade: What You Need To Know ↗
Guggenheim Partners upgraded shares of Biogen Inc (NASDAQ: BIIB) to Buy, citing the company's potential for growth driven by its Alzheimer's disease (AD) and major depressive disorder (MDD)... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗
 
Via Benzinga
News headline image
Looking At Biogen's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today ↗
 
Via Benzinga
News headline image
Biogen Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
These Analysts Revise Price Targets On Biogen Following Q1 Results ↗
Biogen Inc. (NASDAQ: BIIB) reported results for its first quarter. 
Via Benzinga
News headline image
Despite Its Falling 92%, Cathie Wood Is Buying More of This Growth Stock ↗
Wood is betting that Ginkgo Bioworks' biofoundry can scale up enough to become profitable. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review ↗
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
News headline image
Biogen On The Hunt ↗
Biogen is in the process of culling its pipeline to prepare for its upcoming deal making. What is happening and what does it mena? 
Via Talk Markets
News headline image
Earnings Outlook For Biogen ↗
 
Via Benzinga
News headline image
What Does Biogen's Debt Look Like? ↗
 
Via Benzinga
News headline image
P/E Ratio Insights for Biogen ↗
 
Via Benzinga
News headline image
Is Biogen Stock a Buy Now? ↗
The company's fascinating saga in the Alzheimer's disease drug market continues. 
Via The Motley Fool
News headline image
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy ↗
Here are three biotech stocks with promising innovations that could provide catalysts for their respective stocks in 2023 
Via InvestorPlace
News headline image
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA ↗
The FDA approved Biogen Inc's (NASDAQ: 
Via Benzinga
News headline image
Alphabet To Rally Around 36%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
Morgan Stanley raised the price target for Alphabet Inc. (NASDAQ: GOOGL) from $135 to $140. Morgan Stanley analyst Brian Nowak maintained an Overweight rating. Alphabet shares fell 1% to $102.83 in... 
Via Benzinga
News headline image
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
From Biogen Inc.
Via GlobeNewswire
News headline image
What's Going On With Biogen Stock Tuesday? ↗
Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.  
Via Benzinga
News headline image
Biogen Inc. Beats Q1 Earnings And Revenue Estimates ↗
Biogen Inc. came out with quarterly earnings of $3.40 per share. 
Via Talk Markets
News headline image
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs ↗
 
Via Benzinga
News headline image
Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful ↗
The company is hopeful for maintenance dosing and a new injection of the drug. 
Via Investor's Business Daily
News headline image
3 Top Biotech Stocks Defying the Bear Market ↗
All three companies have therapies with strong sales potential. 
Via The Motley Fool
News headline image
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
News headline image
Why Shares of Keros Therapeutics Jumped This Week ↗
The company appointed a new director and an analyst reiterated his position on the stock. 
Via The Motley Fool
News headline image
Biogen To Report Q1 Earnings: Here's What To Expect ↗
We expect Biogen to beat expectations when it reports first-quarter 2023 results on Apr. 25 before the market opens. In the last reported quarter, the company delivered an earnings surprise of 15.38%. 
Via Talk Markets
News headline image
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes! ↗
Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid... 
Via Benzinga
News headline image
Better Big Biotech Buy: Biogen vs. Vertex ↗
One is slightly cheaper than the other. 
Via The Motley Fool
News headline image
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So ↗
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.